Clinical trial · Observational
Polycystic Ovary Syndrome and BETATROPHIN
Can the Betatrophin be a Reliable Marker of Insulin Resistance in Normal Weight and Overweight Women With Polycystic Ovary Syndrome?
NCT04448730CI-TRIAL-00045693completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an original study giving an information about the association body mass index, polycystic ovary syndrome and betatrophin.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Obesity | — | UNRESOLVED | — |
| Polycystic Ovary | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| serum marker levels | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group 1 (normal weight with PCOS )
- description
- 35 cases
- interventionNames
- Diagnostic Test: serum marker levels
- label
- overweight PCOS
- description
- 38 cases
- interventionNames
- Diagnostic Test: serum marker levels
Primary outcomes (1)
- measure
- serum Betatrophin levels
- timeFrame
- 30 min
- description
- ng/L
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: -Polycystic ovary syndrome according to 2003 Rotterdam PCOS Consensus diagnostic criteria Exclusion criteria * pregnancy, * an additional systemic disease (i.e.,hyperprolactinemia, thyroid dysfunction, liver or kidney diseases, cardiovascular disease, hyperlipidemia, type 1 or type 2 diabetes, chronic or acute infection within the previous 30 days), * morbid obesity, * smoking, * the use of medications for contraception, androgen excess, hypertension, hyperglycemia or dyslipidemia at least 3 months before the study.
References
Publications (0)
Data not yet available
No reference posted for this study.